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Objective: The aim of this study was to assess the prognostic and predictive values of circulating tumor cell (CTC)
analysis in colorectal cancer patients.
Patients and methods: Presence of CTCs was evaluated in 60 colorectal cancer patients before systemic
therapy - from which 33 patients were also evaluable for CTC analysis during the first 3 months of treatment - through
immunomagnetic enrichment, using the antibodies BM7 and VU1D9 (targeting mucin 1 and EpCAM, respectively),
followed by real-time RT-PCR analysis of the tumor-associated genes KRT19, MUC1, EPCAM, CEACAM5 and BIRC5.
Results: Patients were stratified into groups according to CTC detection (CTC negative, when all marker genes were
negative; and CTC positive when at least one of the marker genes was positive). Patients with CTC positivity at baseline
had a significant shorter median progression-free survival (median PFS 181.0 days; 95% CI 146.9-215.1) compared with
patients with no CTCs (median PFS 329.0 days; 95% CI 299.6-358.4; Log-rank P < .0001). Moreover, a statistically
significant correlation was also founded between CTC detection during treatment and radiographic findings at the 6
month staging. This correlation applied to CTC results before therapy (odds ratio (OR), 6.22), 1 to 4 weeks after beginning
of treatment (OR, 5.50), 5 to 8 weeks after beginning of treatment (OR, 7.94) 9 to 12 weeks after beginning of treatment
(OR, 14.00) and overall CTC fluctuation during the course of treatment (OR, 20.57).
Conclusion: The present study provides evidence of a strong correlation between CTC detection and radiographic
disease progression in patients receiving chemotherapy for colorectal cancer. Our results suggest that in addition to the
current prognostic factors, CTC analysis represent a potential complementary tool for prediction of colorectal cancer
patients’ outcome. Moreover, the present test allows for molecular characterization of CTCs, which may be of relevance
to the creation of personalized therapies.
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Nowadays, systemic treatment of metastatic cancer can
result in a modest survival improvement for patients.
However, palliation still remains the main treatment goal
for cancer patients with metastatic lesions [1]. Many fac-
tors have been proposed as useful independent prognos-
tic factors of recurrence and overall survival (OS) in
cancer [2-4]. Yet, tumor stage still continues to play a
fundamental role in the management of patients as the
most powerful and reliable predictor of prognosis [5].* Correspondence: Andreia.de.Albuquerque@gmail.com
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distribution, and reproduction in any mediumMoreover, it represents the operational basis for choos-
ing the most appropriate therapy and for evaluating the
efficacy of different therapeutic methods through the
comparison of expected survival rates [6]. Nevertheless,
current prognostic factors do often not allow for a more
personalized approach in cancer treatment and there is a
lack of accurate methodologies to identify patients that
are destined to progress quickly or that would benefit
from a more aggressive therapy.
We recently demonstrated that circulating tumor cell
(CTC) analysis through an in-house optimized assay,
using immunomagnetic enrichment, followed by real-
time RT-PCR detection of a multimarker gene panel,
can be used to isolate and characterize CTCs in a varietyd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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disease-free survival in pancreatic cancer patients [9].
From these feasibility studies, we designed a study to
evaluate the prognostic and predictive values of CTC
analysis in colorectal cancer patients.
Patients and methods
Patients selection and PB sampling
Written informed consent was obtained from all partici-
pants and the study was approved by the local medical eth-
ical committee. Principal inclusion criteria were as follows:
patients with histologically and radiographically proven
colorectal cancer, initiating any first- or second-line sys-
temic therapy. Patients with a history of previous malig-
nancy and patients with active infection were excluded.
From all subjects, 10.0 ml whole blood samples were
collected before therapy in EDTA tubes (Sarstedt AG &
Co, Nümbrecht, Germany) and CTCs were isolated
within 4 h of specimen collection.
Patient follow-up
Patients underwent chemotherapy as appropriate for their
diagnosis and had disease evaluation from their medical
oncologist according to the institutional guidelines. The
evaluation included a physical examination, a complete
blood count, blood chemical tests, screening for serum
tumor markers, radiography and computed tomographic
scan, magnetic resonance imaging, according to tumor
type and stage. The planned re-evaluation for patients with
metastatic disease was performed every 3 months. Re-
sponse was evaluated according to clinical criteria codified
by the Response Evaluation Criteria in Solid Tumors
(RECIST) [10] by a team of medical oncologist and radiol-
ogists. Each disease assessment was classified as complete
response (CR) partial response (PR), stable disease (SD) or
progressive disease (PD). The primary end point for meta-
static patients was time to progression. For response to
therapy in the metastatic setting, the favourable group was
defined as having non progressive (NP) disease (CR, PR
and SD categories) and the unfavourable group was
defined as that with PD or death.
CTCs isolation, mRNA extraction, cDNA synthesis and
multimarker real-time PCR analysis
CTCs were isolated from PB through immunomagnetic
enrichment, using the antibodies BM7 and VU1D9 (target-
ing mucin 1 and EpCAM, respectively), followed by mRNA
extraction, cDNA synthesis and real-time RT-PCR analysis
of the tumor-associated genes KRT19, MUC1, EPCAM,
CEACAM5 and BIRC5. All the methodologies and pri-
mers, as well as real-time RT-PCR validation, have already
been described elswhere [7-9]. According to the analytic
detection limit of our assay, the Cq cut-off, under which a
marker gene is considered to be positive, was defined as:36.0 for KRT19, 37.1 for MUC1, 36.0 for EPCAM, 37.8 for
CEACAM5, 35.0 for BIRC5, 37.3 for SCGB2A2 and 37.9
for ERBB2. A sample was considered to be CTC positive
when at least one of the marker genes was positive.
Statistical analysis
The potential correlation between CTC findings and the
clinicopathological characteristics of the patients was tested
using either a chi-squared test or a Fisher's exact test.
Progression-free survival (PFS) was defined as the time
between the baseline CTC assessment (the initiation of
treatment) and the documentation of first radiographic
disease progression or death. Patients who were alive
and progression free at the time of analysis were cen-
sored using the time between the baseline CTC assess-
ment and their most recent follow-up evaluations. PFS
in CTC-positive and CTC-negative groups was com-
pared with the Kaplan-Meier method, and differences
were tested with the log-rank test.
The association between CTC status during the course
of treatment and radiographic images was assessed by
logistic regression. Patients were classified into two
groups, according to their status after 6 months of initi-
ating a systemic therapy: the favourable group was
defined as having non progressive disease (CR, PR and
SD categories) and the unfavourable group was defined
as that with PD or death. Clinical outcome was then
associated with CTC results obtained before therapy,
after 1–4 weeks, 5–8 weeks and 9–12 weeks of therapy
and with a change in CTC positivity during the course
of treatment. Univariate analyses were performed and
odds ratios (OR) together with the respective 95% confi-
dence intervals (95% CI) were estimated.
A P value < 0,05 was considered to be statistically signifi-
cant. All analyses were carried out using SPSS (Version
17.0, SPSS, Chicago, IL, USA).
Results
Patient characteristics
Between April 2009 and June 2011 a total of 60 colorec-
tal cancer patients, meeting the inclusion and exclusion
criteria, were enrolled. During the median follow-up
period of 242 days (range 191.8 - 292.2 days), evidence
of disease progression was documented in 51 patients
and death had occurred in 17 patients. Detailed clinico-
pathological characteristics of the patients are given in
Table 1.
CTCs at baseline
CTC analysis before treatment revealed that 65.0% of
colorectal cancer patients were CTC positive. Positivity
rates for each individual marker were as follows: 36.7%
for KRT19, 23.3% for MUC1, 30.0% for EPCAM, 26.7%
for CEACAM5 and 16.7% for BIRC5.
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Figure 1 PFS of colorectal cancer patients with and without
CTCs in 10 ml of blood before therapy (CTC positivity is
defined by when at least one marker gene is positive).
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features
The presence of CTCs in the PB of pancreatic patients
at baseline did not correlate with gender (p = 0.218),
stage (p = 0.152), tumor size (p = 0.216), lymph nodes
(p = 0.109) and tumor grading (p = 0.319). However,
associations were found between the presence of metas-
tasis and CTC positivity (p = 0.001).
Correlation between CTCs and PFS in pancreatic cancer
patients
The correlation between PFS and baseline CTCs status
in colorectal patients was compared with the Kaplan-
Meier method and differences were tested using the log-
rank test (Figure 1). PFS was calculated for groups
defined by the presence or absence of CTCs before initi-
ating chemotherapy. The overall median PFS for the as-
sessable patients was 242.0 days (95% CI 191.8-292.2).Patients with CTC positivity at baseline had a significant
shorter median PFS (181.0 days; 95% CI 146.9-215.1)
compared with patients with no CTCs (median PFS
329.0 days; 95% CI 299.6-358.4; Log-rank P < .0001).
Correlation between CTCs and radiographic images
A total of 33 colorectal cancer patients were also eva-
luable for the analysis of CTC status before therapy
and after 1 to 4, 5 to 8 and 9 to 12 weeks of treat-
ment. In this set of patients, 48.5% were classified as
having disease progression at the 6 month staging.
From the 16 patients with PD or death, 14 (87.5%)
were CTC positive before starting a new line of ther-
apy, 12 (75.0%) had positive CTC in their PB at 1 to 4
and 5 to 8 weeks of treatment, and 13 (81.3%) patients
were CTC positive at 9 to 12 weeks after starting
treatment (Table 2).
The predictive value of CTC analysis before therapy
and after 1 to 4, 5 to 8 and 9 to 12 weeks of treat-
ment, as well as the overall fluctuation of CTC positiv-
ity during the course of treatment is shown in Table 3.
Significant associations were found between CTC ana-
lysis at all time points and radiographic outcome at 6
month restaging, being CTC fluctuations the variable
with the strongest correlation. That is, patients with
an increase in the number of positive marker genes,
during the course of therapy, had 20.57 times the odds
of radiographic disease progression compared with
patients who had no CTCs or a decrease in CTC posi-
tive markers.
Table 2 Type and line of therapy, treatment response and CTCs results before and during the course of therapy from
33 colorectal cancer patients







1–4 weeks 5–8 weeks 9–12 weeks
5 FOLFIRI+Beva 2 PD + - - +
7 FUFOX 2 PD + + + +
8 FOLFIRI+Beva 2 NP + + + -
9 FUFIRI 2 PD + + + +
15 FOLFIRI 1 PD - + + +
36 FOLFOX-4 1 PD + - + +
39 FUFIRI 2 PD + - - -
47 FOLFIRI+Beva 1 NP + - - -
49 FOLFOX-4 1 NP + - + -
49 FOLFIRI 2 PD + + + +
65 Panitumumab 2 NP - - + -
65 Panitumumab 2 PD + + + +
70 FOLFOX-4 1 NP - - + -
73 FOLFOX-4 1 PD + - - +
74 FOLFIRI+Beva 2 PD + + + +
77 AIO+Beva 1 NP + + + -
80 FOLFIRI+Beva 1 NP - - - -
81 FUFIRI 1 PD - + + +
81 FUFOX 2 PD + + + +
87 AIO 1 NP + - - +
91 AIO +Beva 2 NP - - - -
97 FOLFIRI +Beva 1 NP + + + +
97 FOLFIRI +Beva 1 PD + + + -
99 FOLFOX-4 1 NP - - - -
109 AIO 1 PD + + + +
112 FOLFIR+Beva 1 NP - + - -
139 FOLFIR+Beva 1 NP + + - -
150 AIO +Beva 1 NP - - - -
151 FUFOX 1 NP + + - +
151 FUFOX 1 PD + + + +
171 FOLFOX-4 1 NP + - - -
184 AIO 1 NP - - - -
195 AIO 1 PD + + + +
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To the best of our knowledge, here we report the first study
using mucin 1- and EpCAM-based immunomagnetic en-
richment, followed by real-time RT-PCR analysis of KRT19,
MUC1, EPCAM, CEACAM5 and BIRC5, as a way to detect
and evaluate the prognostic and predictive effect of CTCs
in PB of colorectal cancer patients.
As treatment has become more effective for colorectal
cancer, decision making has also become more compli-
cated. Five classes of drugs are currently available fortreatment and therefore selection and monitoring of
therapy have become more difficult [11]. Standard prac-
tise is to change treatment after several weeks or months
of therapy if there is evidence of progression. However,
after initiation of systemic treatment, current method-
ologies do not often allow for an accurate and early as-
sessment of clinical benefit. Thus, patients may be either
treated for prolonged periods with an inactive therapy or
a potentially active therapy may be discontinued prema-
turely [1]. Therefore, we have evaluated whether CTC
Table 3 The predictive value of CTCs before and during
the course of treatment in colorectal cancer patients
when compared with 6 months clinical outcome assessed
by radiographic images
Variable Odds ratio (95% CI) P
CTCs before therapy (pos vs neg) 6.22 (1.07-36.21) 0.042
CTCs after 1–4 weeks of therapy
(pos vs neg)
5.50 (1.22-24.81) 0.027
CTCs after 5–8 weeks of therapy
(pos vs neg)
7.94 (1.60-39.42) 0.011
CTCs after 9–12 weeks of therapy
(pos vs neg)
14.00 (2.60-75.41) 0.002
CTCs fluctuations during therapy
(increase vs decrease)
20.57 (2.17-194.95) 0.008
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treatment benefit in advance of radiographic changes.
In the present study, we report the results of an in-
house immunomagnetic/real-time RT-PCR assay for the
detection and characterization of CTCs in colorectal
cancer patients. Assay development and validation
(addressing typical technical concerns, such as specifi-
city, contaminants, efficiency, sensitivity and sample
quality), are extensively explained elsewhere [7-9]. By ap-
plying this methodology, our results show a correlation
between CTC assessments and radiographic determina-
tions of disease progression in patients receiving chemo-
therapy for metastatic colorectal cancer. This correlation
applies not only for CTC results obtained during the
treatment, but also to CTC assessments obtained as far
in advance as 6 months before imaging. Moreover, fluc-
tuations in CTC levels during the course of treatment
were also associated with tumor responsiveness deter-
mined by radiographic imaging. Patients with an in-
crease in the number of positive markers, during the
course of therapy, had 20.57 times the odds of radio-
graphic disease progression compared with patients who
had no CTCs or a decrease in CTC positive markers.
Therefore, our findings suggest that serial CTC assess-
ments taken before and during the first 3 months of
treatment, used in conjunction with imaging, could help
to confirm evidence of tumor response or decide doubt-
ful findings.
Analysis of CTCs in blood of cancer patients can be per-
formed by several rare cell detection techniques and prom-
ising results with potential clinical relevance have been
obtained. One of the largest published studies on CTC de-
tection in metastatic colorectal cancer, involving 430
patients, was performed by Cohen et al. [12]. Patients had
their blood collected before treatment and at four different
points during treatment schedule and CTCs were detected
using the CellSearchW System. Patients were stratified
according to favourable (< 3 CTCs per 7.5 ml of blood) or
unfavourable (≥ 3 CTCs per 7.5 ml of blood) CTCs counts.The study showed that, at all time points, median PFS and
OS rates were twice as high for patients in the favourable
group as compared to those in the unfavourable group.
The study also found a significant prognostic correlation
between patient grouping by image response and CTCs,
meaning that if patients presented elevated CTCs after
therapy, they were more likely to have a worse prognosis.
An update of this study, 1 year later and enclosing
extended follow-up times, reported a pronounced PFS and
OS difference between favourable and unfavourable
groups, mostly in patients receiving first-line therapy [13].
Our study, even if using another CTC detection
method and a smaller cohort of patients, confirms not
only the previous findings by Cohen et al., but gives also
extra information about CTC phenotypes. To date, a
variety of research methods have been developed to iso-
late and enumerate CTCs. The existing CTC detection
assays rely on various properties of CTCs, with each one
having unique advantages and limitations. However, no
enrichment or detection method has yet proven to be
the golden standard and continuing efforts are needed
to improve the reliability of CTC detection techniques.
Even if the CellSearchW System has been validated via
multicenter studies and is the only FDA cleared device
for enumeration of CTCs, its use presents some limita-
tions that may be crucial for elucidating and optimizing
the use of CTCs in cancer management. By simply enu-
merating tumor cells, the CellSearchW System is missing
information regarding the enormous biological and clin-
ical contributions that CTCs can provide [14]. Therefore
the future of rare tumor cell analysis relies also in the
development of sensitive and relatively inexpensive
assays capable of generating CTC molecular profiles,
which may allow for the identification of subgroups of
patients who would benefit from a specific therapy.
Nevertheless, limitations of this work must be consid-
ered. The study population was relatively small which
may influence the interpretation of the results. However,
small well-designed studies are of great value once that
they can provide results quickly and becoming part of a
preliminary selection in order to further design larger
confirmatory studies. Patients also had flexibility regard-
ing the exact dates of blood draws and computed tom-
ography scans. However, the time frames for data
analysis were well defined and this flexibility reflects the
everyday in clinical practice.
Conclusion
Our results suggest that the optimal cancer staging sys-
tem should include both anatomic and non anatomic fac-
tors, such as CTCs. In addition to strictly tumor-related
descriptors, there are also genetic characteristics (gene
expression profiling patterns, clustering of genetic altera-
tions and multimarker phenotypes) that represent
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These tests could become an integral part of a future sta-
ging system, in association with more traditional morpho-
logic features, able of enhancing the prediction of patient
outcome and ultimately allowing tailored therapy and
improved patient care. The present study provides not only
evidence of a strong correlation between CTC detection
and radiographic disease progression in patients receiving
chemotherapy for colorectal cancer, but offer also the pos-
sibility of molecular characterization of CTCs, which may
imperative to the creation of personalized therapies.
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